Introduction
============

Primary bone lymphoma (PBL) is a peculiar extranodal presentation of non-Hodgkin's lymphoma. Primary bone diffuse large B-cell lymphoma (DLBCL) is the most common pathological type, comprising about 80% of PBL. Diagnosis of PBL depends on the combined clinical examination and imaging studies, and is confirmed with immunohistochemical examination. Due to the rarity of this disease, more relative studies and case reports are needed to provide insight about this obscure lymphoproliferative malignancy. Here, we report one rare case of primary bone DLBCL involving the distal radius. Meanwhile, clinical, imaging, and immunohistochemical aspects, therapeutic options, and related literature review are discussed.

Case presentation
=================

A 44-year-old man was hospitalized with a history of untreated diabetes, a 2-month history of left-sided distal forearm pain and swelling, and development of progressive limited motion of the left wrist of 1 month duration. At the time of initial presentation, he had left-sided distal forearm pain accompanied with a slight swelling, without fever, weight loss, or fatigue. He had undergone X-ray screening of the left-sided upper extremity in other hospital and the result showed a sheet-like, worm-eaten bone destruction area in the left-sided distal radius. The localized bone cortex was completely or partially discontinuous ([Figure 1](#f1-ott-9-4923){ref-type="fig"}). After 1 month, with aggravated pain, swelling of left-sided distal forearm, and progressive limited motion in the left wrist, the patient was admitted to our hospital and underwent Magnetic Resonance Imaging, which demonstrated a sheet-like bone destruction area in the left-sided radius, localized discontinuous bone cortex, and adjacent soft tissue masses, hinting at primary bone malignancy ([Figure 2](#f2-ott-9-4923){ref-type="fig"}). He denied a history of fever of unknown origin and viral infection. Clinically, still the patient had no other symptoms, including fever, weight loss, or fatigue. The physical examination only revealed a slight prominence when palpating the left-sided distal forearm and wrist, without any palpable hepatosplenomegaly or lymphadenopathy. Laboratory tests including the routine viral test were almost normal except blood glucose (8.1 mmol/L) and alkaline phosphatase (134 U/L). Computed tomography (CT) results of brain, thorax, and abdomen were normal, and the bone marrow aspiration smear did not show neoplastic involvement. A bone biopsy of the lesion and the pathological examinations suggested a diagnosis of primary bone DLBCL. Immunochemical results showed CD20+, CD5+, PAX-5+, MUM-1+, CD3−, CD45RO−, CK−, vimentin−, myogenin−, CD30−, CD10−, Bcl-6−, and Ki67+ (70%), which demonstrated DLBCL, non-germinal center B-cell-like (non-GCB) ([Figure 3](#f3-ott-9-4923){ref-type="fig"}). According to the Ann Arbor staging, the patient was I EA stage of the disease, International Prognostic Index (IPI) score 0. The patient first received four cycles of concurrent chemotherapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). Then he received radiotherapy (RT). The total dose was 32 Gy/16 fractions. The patient was followed up every 6 months. Up to now, 6 months after treatment, there has been no evidence of recurrence either clinically or radiologically. Informed consent was obtained from the patient for publication of this case report.

Discussion
==========

According to the World Health Organization classification of tumors of the soft tissue and bone in 2013,[@b1-ott-9-4923] PBL is defined as a single skeletal lymphoma with or without regional lymph node involvement, and multiple bone lesions without visceral or lymph node involvement. Its underlying causes are still largely unknown.

According to rare previous reports,[@b2-ott-9-4923]--[@b7-ott-9-4923] PBL patients generally are characterized by localized bone pain, soft tissue swelling, and possibly a palpable lump in the lesion site. It commonly develops in patients aged between 20 and 50 years, reveals a male preponderance, and the morbidity rate of males is slightly higher than females.[@b8-ott-9-4923] The predilection site of PBL is the femur, accounting for 29% of all cases, and other sites include the pelvis, humerus, skull and neck, and the tibia.[@b8-ott-9-4923],[@b9-ott-9-4923] The pooled statistical analysis in the IELSG-14 study shows a low incidence of primary DLBCL bone lymphoma involving the forearm (5.6%) in PBL patients.[@b9-ott-9-4923]

Our patient first presented with distal forearm pain, swelling, and X-ray screening of the left-sided upper extremity showing an osteolytic lesion of his radius. The differential diagnosis included PBL and other primary malignant bone tumors. However, PBL accounts for onlŷ5% of the extranodal lymphomas, \<1% of all non-Hodgkin's lymphomas, and merely about 3%--7% of the malignant bone tumors;[@b8-ott-9-4923] however, all of them could cause pain and swelling in the position of bone lesion. Besides, the radiographic findings of PBL are atypical: bone X-ray usually presents as lytic or osteoblastic lesion, or lesions could even coexist in the same bone;[@b10-ott-9-4923] therefore, it is hard to distinguish the conditions. However, Magnetic Resonance Imaging reveals the extent and details of lesions more clearly than CT with respect to cubital bones and joints, though the standard contrast-enhanced CT scan is the primary modality for staging, restaging, and follow-up of lymphoma patients.

18FDG positron emission tomography/computed tomography(PET/CT) may have a higher sensitivity and specificity than standard CT scan and was recommended by Lugano Classification as a standard tool for the initial evaluation, staging, and response assessment of FDG-avid lymphomas; however, it is only supported by small retrospective studies in lymphoma patients[@b11-ott-9-4923] and has not been confirmed in PBL.

The clinical manifestations and imaging are nonspecific with limitations to distinguish PBL from other primary bone tumors such as Ewing's sarcoma, osteogenic sarcoma, and chondrosarcoma. Therefore, diagnostic samples obtained by surgical procedure and immunohistochemical tests are indispensable for clinicoradiological confirmation of PBL and for differential diagnosis. Other surgical procedures, especially excision of lesions, should be avoided whenever possible, unless the involved weight-bearing bones are destroyed extensively or pathological fracture is present in bone lesions.[@b12-ott-9-4923],[@b13-ott-9-4923]

DLBCL is the most common pathological type either primarily or secondarily infiltrating the skeleton, accounting for about 70%--80% of all PBL,[@b8-ott-9-4923] with rare to anecdotal occurrences of follicular, marginal zone, lymphoplasmacytic, anaplastic large cell, natural killer/T-cell, Burkitt, and Hodgkin lymphomas. Tumor cells are generally immunoreactive for the B-cell markers CD20, CD21, CD45, and CD79a.[@b14-ott-9-4923],[@b15-ott-9-4923]

With the progression of treatment strategies including rituximab and RT which are widely applied in primary bone DLBCL, discrepancies now mostly focus on immunotherapy and RT in rituximab era. Rituximab has essentially changed the natural behavior of DLBCL, especially the primary extranodal disease. A large retrospective study of localized DLBCL and the MINT trial both suggested that patients with primary extranodal disease benefited from the addition of rituximab,[@b16-ott-9-4923],[@b17-ott-9-4923] while rituximab failed to improve the outcome of patients with DLBCL with skeletal involvement.[@b18-ott-9-4923] Also, the survival benefit of the addition of rituximab to CHOP in primary bone DLBCL is still controversial. A retrospective British Columbia Cancer Agency study of primary bone DLBCL reported significant improvement in 3-year progression-free survival (PFS) for patients treated with rituximab compared to those who were not (88% vs 52%, respectively).[@b19-ott-9-4923] However, it was questioned by a recent retrospective trial by Tao et al, which insisted that rituximab did not improve outcomes for patients with primary bone DLBCL and speculated that perhaps skeletal DLBCL is a biologic subtype with some resistance to rituximab.[@b20-ott-9-4923]

The role of consolidation RT has also been the subject of much debate over the past decades as more trials have emerged that can address the role of RT in the rituximab era. Whether the addition of consolidation RT can improve outcome is still disputable according to a recent retrospective trial series of DLBCL and bulky residual masses.[@b17-ott-9-4923],[@b18-ott-9-4923],[@b21-ott-9-4923] In the prospective RICOVER-60 study for elderly aggressive B-cell lymphoma patients, PFS and overall survival (OS) were found to be inferior without additive RT.[@b22-ott-9-4923] Regarding primary bone DLBCL, the IELSG-14 study also reported that the addition of consolidative post-chemotherapy RT does not further improve the outcome, with both chemo-radiotherapy and chemotherapy alone producing a 5-year PFS of 74% and 67%, respectively.[@b9-ott-9-4923] The British Columbia Cancer Agency study suggested that patients who received RT had significantly worse 10-year OS than those who received chemotherapy alone (25% vs 56%, *P*=0.025), and the researchers stated that they could not reach conclusions about the role of RT.[@b19-ott-9-4923] On the contrary, the retrospective Rare Cancer Network study suggested anthracycline-based chemotherapy by involved-field RT as the first-line treatment for patients with primary bone DLBCL and one of the favorable prognostic factors for OS and lymphoma specific survival was an RT dose \>40 Gy (*P*=0.005).[@b23-ott-9-4923] Randa et al reported that receiving RT was associated with improved 5-year PFS and had a trend toward an OS benefit, while no significant difference in PFS or OS was found between patients treated with 30--35 Gy versus 36 Gy.[@b20-ott-9-4923] In the IELSG-14 study, there was no significant survival difference between the doses \<36 Gy and \>36 Gy in primary bone DLBCL patients.[@b9-ott-9-4923] Compared with previous standard doses of 40--45 Gy, a radiation of 30 Gy is not associated with loss of efficacy in aggressive lymphoma and with no significant differences in in-field relapse rate, PFS and OS.

Although the roles of consolidation RT and rituximab are still in dispute, our patient was benefited and has not relapsed until now. In early-stage disease, relapses occur equally within and outside the primary sites of disease, with local and systemic relapse rates being 10% and 17%, respectively.[@b23-ott-9-4923] Many unconfirmed prognostic factors have been reported in earlier retrospective studies.[@b9-ott-9-4923],[@b19-ott-9-4923],[@b20-ott-9-4923],[@b23-ott-9-4923] Conventional IPI plays a prognostic role in patients with advanced-stage DLBCL with skeleton involvement, but not in polyostotic lymphoma and PBLs.[@b9-ott-9-4923] Age, performance status, and serum lactate dehydrogenase levels, the three remaining IPI variables,[@b9-ott-9-4923] and other factors could be used to evaluate the prognosis.
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![Sheet-like, worm-eaten bone destruction area is shown in the left-sided distal radius X-ray and localized bone cortex is completely or partially discontinuous.](ott-9-4923Fig1){#f1-ott-9-4923}

![MRI and enhanced MRI: coronary, lateral, sagittal axis.\
**Notes:** MRI shows sheet-like bone destruction area in the left-sided radius, completely or partially discontinuous localized bone cortex, and adjacent soft tissue masses with low-signal intensity on T1-weighted images (**A**). T2-weighed images show heterogeneous high signal of (**B**) coronary axis, (**C**) lateral axis. Enhanced scanning shows heterogeneous enhancement of (**D**) coronary axis, (**E**) lateral axis, (**F**) sagittal axis.\
**Abbreviation:** MRI, magnetic resonance image.](ott-9-4923Fig2){#f2-ott-9-4923}

![Pathology and immunophenotyping of primary bone diffuse large B-cell lymphoma, non-GCB (×400). (**A**) CD20+, (**B**) CD5+, (**C**) PAX-5+, (**D**) MUM-1+, (**E**) Ki67+.\
**Abbreviation:** non-GCB, non-germinal center B-cell-like.](ott-9-4923Fig3){#f3-ott-9-4923}
